PANC 08.13 Cells

The PANC 08.13 cell line, also known as PL9, is a pancreatic cancer cell model derived from adenocarcinoma. It has been included in studies focused on understanding genomic variations, including allelic loss, homozygous deletions, and broader chromosomal instability. This cell line is part of an extensive set of pancreatic cancer models used to analyze somatic alterations in cancer cells, particularly in the absence of matched normal tissues, making it ideal for high-resolution genetic mapping.

In a study utilizing Affymetrix 100K SNP arrays, PANC 08.13 was examined alongside 25 other pancreatic cancer cell lines. These arrays allowed for high-density analysis of single nucleotide polymorphisms (SNPs) and revealed the allelic status across the genome without requiring matched normal samples. Such studies help identify critical regions of allelic loss (LOH), gene deletions, and chromosomal recombination events, which are frequent in pancreatic cancer cells.

PANC 08.13’s genetic characterization includes frequent mutations in driver genes typically associated with pancreatic cancer, such as KRAS, TP53, CDKN2A, and SMAD4. These genetic defects are hallmarks of pancreatic ductal adenocarcinoma and contribute to uncontrolled cellular proliferation, disrupted cell cycle regulation, and defective apoptosis mechanisms. Studies leveraging cell lines like PANC 08.13 allow for the development of targeted therapies and the identification of novel therapeutic vulnerabilities in pancreatic cancer.